Gingival Overgrowth, Gingival Hyperplasia
Conditions
Brief summary
This study evaluates the clinical and biochemical effects of injectable platelet-rich fibrin (i-PRF) on wound healing after gingivectomy, a surgical procedure used to treat gingival overgrowth. Using a split-mouth design, i-PRF was applied to the surgical site on one side of the mouth (test group), while the other side was treated with conventional gingivectomy alone, without any additional material (control group). Clinical periodontal parameters (plaque index, gingival index, probing depth, clinical attachment level, and bleeding on probing) were assessed at baseline, before surgery, and 28 days after surgery. Additionally, levels of PDGF, IGF-1, and IL-18 in gingival crevicular fluid were measured before surgery and on the third postoperative day to evaluate the biochemical impact of i-PRF on wound healing. A total of 31 participants aged 15-50 years were included in the study.
Interventions
BIOLOGICALinjectable Platelet-Rich Fibrin (i-PRF)
Autologous injectable platelet-rich fibrin, prepared by centrifugation of the patient's own venous blood, applied directly to the gingivectomy wound site.
PROCEDUREConventional Gingivectomy
Standard surgical excision of overgrown gingival tissue using periodontal knives.
Sponsors
Şeyma Çardakçı
Afyonkarahisar Health Sciences University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Intervention model description
In this split-mouth study, the contralateral side (right) received conventional gingivectomy followed by application of injectable platelet-rich fibrin (i-PRF) to the wound site.
Eligibility
Sex/Gender
ALL
Age
15 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
Achieving an optimal level of oral hygiene following Phase I periodontal therapy * Presence of bilateral, symmetric chronic inflammatory gingival overgrowth in the anterior mandibular or maxillary region * Absence of attachment loss and bone loss at the surgical site * Absence of systemic conditions that could affect wound healing and periodontal surgical outcomes, such as uncontrolled diabetes, cancer, HIV, or metabolic bone diseases * No use of systemic corticosteroids, immunosuppressive agents, radiotherapy, and/or chemotherapy prescribed or taken within 2 months prior to the study intervention, which could affect study outcomes, wound healing, and the coagulation mechanism * Normal physiological hormonal balance
Exclusion criteria
Patients unable to achieve optimal oral hygiene or with poor compliance/communication * Presence of any systemic disease adversely affecting periodontal health and post-procedural wound healing (e.g., diabetes, rheumatoid arthritis, neurological disorders, pulmonary and renal diseases) * Use of medications known to cause gingival overgrowth, including immunosuppressants, anticonvulsants, and calcium channel blockers * Pregnancy or lactation in female participants * Presence of moderate to advanced gingivitis or periodontitis * Current smoking
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Gingival Crevicular Fluid (GCF) IL-18, IGF-1 and PDGF Levels | Immediately before surgery (baseline) and postoperative day 3 |
Countries
Turkey (Türkiye)
Outcome results
None listed